Compare Infosys Limited (INFY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Novo Nordisk A/S — how do they compare? Infosys Limited trades at $10.8 (market cap $41.74B), while Novo Nordisk A/S trades at $38.38 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 4× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Novo Nordisk A/S for 116 Days on average.
| INFY | NVO | |
|---|---|---|
Market Cap | $41.74B | $165.31B |
Volume | 31,354,285 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $20.22 | $63.98 |
52-Week Low | $10.49 | $35.29 |
Typical Hold Time | 27 Days | 116 Days |
Enterprise Value | $39.48B | $179.56B |
Dividend Yield | 4.89% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.78, up 2.18% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025 with a net income margin of 16.37%, and recent earnings show mixed results with a beat in Q1 2026 but a miss in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, highlighting growth initiatives in technology services.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings, but institutional activity shows increased holdings, supporting a stable foundation for recovery.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
